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ABSTRACT
Background
Hepatitis B and ART have been established to cause liver damage. We compared the 
changes in the levels of Alanine amino Transferase (ALT) in HBV/HIV co-infected and 
HIV infected women on ART to determine liver disease among women on ART in 
Lilongwe Malawi using Data from the BAN study.
Methods
We conducted a secondary data analysis from The BAN study to investigate the 
changes in the levels of ALT among HIV/HBV co-infected and HIV mono-infected 
women who were randomised into the maternal ART arm. In brief The BAN study 
assessed the benefit of nutritional supplementation given to women during 
breastfeeding, the benefit and safety of antiretroviral medications given either to 
infants or to their mothers to prevent HIV transmission during breastfeeding and the 
feasibility of exclusive breastfeeding followed by early, rapid breastfeeding cessation. 
ALT was monitored up to 48 weeks with an average of 12 follow-ups per individual. 
Continuous variables i.e. Age, ALT and CD4 count were compared between HIV/HBV 
co-infected women and HIV mono-infected women using the Wilcoxon rank sum test. 
Multiple regression analyses were performed using longitudinal data Generalised 
Linear mixed models to evaluate the relationship between ALT and HIV/HBV co­
infection, among HIV-infected women, controlling for ART regimen, CD4 count and 
visit. All individuals were included in the analysis regardless of the different numbers 
of follow-up visits. To show the change of ALT levels longitudinal line graphs were 
used. Predictions of ALT levels per visit were also plotted using margin plots.
Results
The study subjects comprised of 544 women of whom 5.6% were HIV/HBV co­
infected. The age range of the study population was 16-45 years. Median age at 
enrolment was 26(IQR: 22-29). The median ALT enzyme level of HIV/HBV co-infected 
individuals was slightly higher at baseline (13 UI/L (10-16) vs 14 UI/L (11-18, p=0.10) 
and at the last follow-up (17UI/L (14-22) vs 19 UI/L (16-26, p=0.04) compared to HIV 
mono-infected counterparts. HIV/HBV co-infection women were 3.28 times (1.43-9.03 
p= 0.01) more likely to have abnormal ALT, compared to their mono-HIV infected 
counterparts. Individuals that were initiated on Nelfinavar as first line ART were 3.22
times (1.85-5.59 p=0.001) more likely to have elevated ALT compared to those that 
were initiated on LPV/r based regimen. Moderately immune suppressed women (CD4 
count of between 200 to 500 cells/dl) were 0.38 times less likely to have elevated 
ALT(0.15-1.00) while women who were severely immune suppressed had 3.51 times 
more likely to have abnormal ALT . Overall there was an increase in the level of ALT 
per each subsequent visit.
Conclusion
Individuals co-infected with HIV/HBV generally had higher levels of ALT compared to 
HIV mono-Infected individuals and this increased over time. The current study 
suggests that monitoring of ALT in patients co-infected with HIV/ HBV on ART should 
be performed regularly, and the caution should be taken when prescribing first line 
ART.
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CHAPTER ONE
1.0 INTRODUCTION
1.1 Background
Of the 40 million people currently living with HIV/AIDS worldwide, 70% reside in sub­
Saharan Africa (SSA) (1)2) . Malawi has a generalized HIV epidemic with a 
prevalence of 10.6% among adults (15-49 years old) as of 2010. In 2012 it was 
estimated that about 1.1 million out of 17.74 million people were living with HIV. AIDS 
still remain the leading cause of death amongst adults in Malawi, it affects the life 
expectancy. In contrast, the number of people living with active hepatitis B virus 
(HBV) infection worldwide is estimated to be at least six times higher than that of those 
infected with HIV(3). At least 275 million people worldwide are estimated to be chronic 
carriers of HBV, representing over 5% of the global population. HBV is endemic in 
sub-Saharan Africa (4), the general carrier rate in SSA’s general population is from 5­
20%
The prevalence of hepatitis B surface antigen (HBsAg) seropositivity among HIV 
infected individuals is ten times higher than in the general population (5). Due to 
shared modes of transmission, Co-infection with HIV and hepatitis B virus is common. 
HBV prevalence among HIV infected individuals varies with population studied 
nevertheless many studies have shown increased prevalence of HBV among HIV 
infected populations in SSA. It is estimated that 7.4% of HIV infected individuals are 
HBV infected. The natural progression of chronic HBV infection is modified in the 
presence of HIV co-infection (6).
The national governments and International donors have made commendable efforts 
in scaling up HIV treatment and care which resulted into a large scale roll out of 
ART(7). The large scale availability of ART has resulted in a decrease in the mortality 
and morbidity due to AIDS defining diseases. Following improved life expectancy non­
Aids defining diseases are surfacing as a common cause of death among HIV infected 
individuals with liver disease as a regular cause of mortality. This proportionately high 
liver-related mortality is due to the accelerated course of hepatitis B in HIV- 
seropositive patients (8). Persistent HBeAg reactivity and high levels of HBV DNA in 
the blood have been associated with an accelerated progression of hepatitis B in HIV
co-infected persons. The outcomes of HIV/HBV co-infection includes increased liver- 
related morbidity and mortality(6), immune reconstitution to HBV in the setting of ART, 
increased hepatitis B viral replication and hepatotoxicity from antiretroviral drugs(8)(9)
Given the large scale ART roll out the burden of liver disease is expected to increase 
especially in HBV co-infected individuals. Knowledge of the pattern of ALT levels will 
inform the effect of HBV infection among individuals on lifelong ART. This study 
therefore will assess the changes of the levels of ALT to establish liver damage among 
HIV/HBV co-infected women on ART recruited in the Breast feeding Antiretroviral and 
Nutrition (BAN) study Malawi.
1.1.1 Problem Statement
Malawi implemented the new integrated ART/PMTCT guidelines in July 2011 (10). The 
implementation included initiation of life long ART for all HIV infected pregnant and 
breastfeeding women irrespective of their WHO stage and CD4 cell count(10). Such 
a large scale up of ART in the country with high burden of HBV will lead to high risk 
of liver disease (11). The additive effects of HBV on the liver have been studied but 
there is little knowledge among women in Malawi.
Using the BAN study data we conducted a secondary data analysis to assess the liver 
damage using ALT as a proxy. The BAN study assessed the effect of ART in reducing 
MTCT of HIV. Women were followed for 48 weeks post-delivery with biomedical 
monitoring, in addition women were tested for HBV infection at Baseline.
1.1.2 Justification for the Study
With more people getting onto ART knowledge of the risks of ART on those with HBV 
or the extent of liver damage will help in deciding on choice of first line ART. For 
example if HBV is diagnosed before initiation of ART, caution will be taken in the 
prescription of first line ART for those patients who are HIV/ HBV co-infected given the 
high risk of liver damage among these individuals. Drugs such as abacavir, 
saquinaver, Nelfinavir, Lamivudine, Amprenavir and Indinavir may be prescribed as 
first line therapy because they are less toxic to the liver (12). Tenofovir and 
Emtricitabine may be included in the first line ART because they have dual activity 
against HIV and HBV (13). Close monitoring of ALT may help to understand the
patterns of the changes in the levels of ALT which will lead to early diagnosis of liver 
damage.
1.2 Literature Review
1.2.1 Introduction
It is estimated that over 280 million people worldwide are infected with HBV chronically 
(Positive hepatitis B surface antigen positive for over 6 months) while 40 million people 
are infected with HIV. Because of the shared way of transmission, HIV/HBV co­
infection is common, and about 4 million people in the world are HIV/HBV co-infected. 
Studies have reported a relatively high prevalence of HBV in HIV infected populations 
of sub-Saharan Africa with more than 36% of the HIV positive individuals are carrying 
serum markers for HBV. HIV/HBV co-infection is a major public health problem which 
influences morbidity and mortality in sub-Saharan Africa. HBV prevalence among HIV 
infected individuals, is estimated at 4%-24%(9). The common modes of transmission 
are vertical horizontal and early childhood exposure.
1.2.2 HIV burden in Malawi
HIV prevalence in Malawi is among the highest in the world with 10.3% of the 
population living with HIV(3). Malawi contributes 4% of the total number of people 
living with HIV in SSA. In 2011 Malawi adopted option B+ plus which involved lifelong 
ART treatment for all breastfeeding mothers regardless of CD4 count or clinical 
stage(10). In 2012, the number of women on any antiretroviral during pregnancy 
expanded to 20,687 from 13,910 in 2011(10). This was a 49% increase in total 
antiretroviral coverage of known HIV positive pregnant women. With such a large ART 
scale up, the risk of liver disease is expected to be high especially among HBV co­
infected individuals.
1.2.3 HBV Burden
Hepatitis B virus attacks the liver, and it causes acute and chronic liver disease. The 
virus can be transmitted through exposure to infected body fluids or blood. It is 
frequently spread from mother to child during birth (perinatal transmission) in endemic 
areas. Sexual transmission may occur, in unvaccinated men who have sex with men 
and heterosexual persons with multiple sex partners. Less than 5% of adult cases 
progress to chronic hepatitis B (6). In addition transmission of the virus may occur
through the reuse of skin piercing instruments i.e. Needles and syringes either in 
hospital settings or among individuals who inject drugs. It is estimated that 275 million 
people are chronically infected with hepatitis B (defined as hepatitis B surface antigen 
positive for at least 6 months). About 686 000 people die every year due to 
complications of hepatitis B, which includes cirrhosis. Hepatitis B prevalence is high in 
East Asia and sub-Saharan Africa, it estimated that about 5-10% of the adult 
population is chronically infected with hepatitis B virus in Africa and Asia(14).
1.2.4 Phases of HBV Infection
The individual course of HBV infection depends on the interaction between host 
immune system and the virus replication. The phases can be divided into four: immune 
tolerance, immune clearance, low or Non_replicative and reactivation.
1.2.4.1 Immune Tolerant
Patients have HBeAg with high serum levels of HBV DNA but normal or mildly elevated 
ALT and normal or minimal liver histological activity.
1.2.4.2 Immune Active Phase
After a period of HBe Ag positivity, which depends on the age at which infection was 
acquired, the immune tolerance is lost and patients may enter to immune active phase. 
This phase is characterised by fluctuating but decreasing HBV DNA levels and 
increased ALT and Histologic activity indicating immune mediated histologic damage.
1.2.4.3 Low or Non-Replicative Phase
This involves seroconversion from HBeAG to its antibody anti_HBe. This is preceded 
by decrease in serum HBV DNA to below detectable levels, and is referred to carrier 
inactive phase, liver disease is inactive with normal ALT. Inactive phase can last for 
decades or for life.
1.2.4.4 Reactivation Phase
In a few individuals who were initially positive for HBsAG receiving highly active 
antiretroviral therapy (HAART) for HIV infection, HBV-associated episodes of severe 
hepatitis have occurred and mostly were explained by HAART-induced immune 
reconstitution.
1.2.5 HIV/HBV co-infection Prevalence
HIV accelerates the natural progression of HBV infection. The prior presence of HIV 
in HBV patients increases the risk of developing chronic HBV and prolonged ALT 
elevation. HBV/HIV co-infection slows and reduces the rate of HBeAg and HBsAg sero 
conversion, which results into higher prevalence of HBeAg-positive disease. There is 
a link between HIV and reactivation of HBV and increased HBV viral load, despite 
milder levels of serum ALT compared to HBV mono-infected individuals. Despite this 
liver damage progresses more rapidly shortening the period from HBV acquisition to 
Cirrhosis in co-infected individuals and also they have poor response to interferon and 
increased lamivudine resistance. Acute HBV may be accelerated in the presence of 
HIV infection, with a lower incidence of icteric illness and poor clearance of HBV(15). 
HIV increases the risk of cirrhosis and end-stage liver disease in HBV co-infection(16). 
Liver-related disease has emerged as the leading cause of non-HIV-related mortality 
in countries with large coverage of ART(2). Cohort studies have shown risk of liver- 
related mortality to be 2-3 times higher in HIV/HBV co-infected patients than in HIV- 
mono infected patients (14% vs 6%)(5)(6). HIV co-infection is associated with more 
frequent fluctuations of ALT, which result from immune reconstitution inflammatory 
syndrome (IRIS) owing to ART, interruption of HIV/HBV treatment, or the development 
of resistance to HIV/HBV treatment (9).
1.2.6 Effects of ART on the Liver
Listed below are the mechanisms by which ART can cause liver damage mitochondrial 
toxicity, Hypersensitivity reactions, IRIS, Direct drug toxicity or drug metabolism.. IRIS 
is characterized by the worsening of preexisting infectious diseases due to rapid 
immune restoration in the setting of successful HIV RNA suppression. The syndrome 
generally manifests within the first two months of ART initiation and is accompanied 
by a precipitous decline in HIV RNA and rise in CD4 count. In patients with viral 
hepatitis, immune restoration can lead to a clinical hepatitis due to the immune 
response to the virus. There have been case reports of clinical flares of HBV in the 
setting of ART initiation, even with regimens including anti-HBV activity, and of rapidly 
progressive HCV-related cirrhosis associated with ART-related immune restoration 
Co-infection with HBV 2.74 (0.37-5.12). Other risk factors associated with ART-related 
liver injury include pre-existing advanced fibrosis, pre-treatment elevated ALT or AST, 
alcohol abuse, older age, female gender, first exposure to ART, and significant
increase in CD4 cell count after ART initiation, concomitant tuberculosis medications, 
and cocaine use.
While all antiretroviral drugs have some risk of hepatotoxicity, some are more 
implicated than others, and classes of drugs have characteristic patterns of injury. The 
non-nucleoside reverse transcriptase inhibitors (NNRTI's) typically cause either 
hypersensitivity reactions or direct drug toxicity and therefore have two peaks of onset: 
within days to weeks or several months after initiation. Nevirapine (NVP) is the NNRTI 
most associated with hepatotoxicity, though hypersensitivity reactions resulting in liver 
failure have been reported with the newer NNRTI etravirine. Efavirenz can also cause 
hepatotoxicity but does so less frequently than NVP or etravirine.
Ritonavir is known to be hepatoxic while saquinaver, Nelfinavir and Amprenavir and 
Indinavir have shown to be safer protease inhibitors (17). Lamivudine has been 
reported to be effective against both HIV and HBV replication, although it has been 
reported to be resistant to HIV/HBV co-infected individuals recently. Resistance to 
lamivudine was reported in 50% after 2 years and 90% after 4 years of therapy in a 
retrospective cohort study of HIV/HBV-co-infected persons(18).
Tenofovir has recently been reported to be active against both HIV and HBV. Tenofovir 
is a nucleotide reverse transcriptase inhibitor, and it has been shown to have potent 
in vitro activity against both wild-type and lamivudine-resistant HBV. In pilot studies, 
Tenofovir demonstrated anti-HBV activity in HIV/ HBV co-infected patients. HBeAg 
sero-conversion was observed in a quarter of the cases after 52 weeks of treatment.
1.2.7 Alanine Amino Transferase as an Indicator of Liver Damage
Alanine aminotransferase (ALT) is a liver enzyme used to measure the liver damage 
in resource limited settings. Elevated levels of ALT are associated with liver damage 
and mortality (7). Measurement of ALT is critical in the diagnosis and assessment of 
liver damage. ALT has a longer half-life compared to the other liver enzymes which 
makes it very useful in monitoring liver damage. ALT is measured in blood as part of 
Liver function tests. Hepatitis B virus infection is the common aetiology of elevated 
ALT values. HBV infection is frequently asymptomatic and is sometimes discovered 
because of an elevated ALT level identified upon routine blood test (8). Elevated levels
of ALT (>43 UI/L) are associated with progression of liver disease and development 
of morbidity. ALT is used to test liver disease and treatment initiation and predicting 
the progression of the infection in future (19)(20). Hepatitis is associated with elevated 
ALT levels which indicate liver damage, known to be prevalent in patients who are on 
ART. However, studies of Tenofovir treatment of a larger patient population and for a 
longer period are necessary to assess the extent and durability of HBV suppression 
with this drug.
1.2.8 Summary of Literature review
Based on the studies that have been conducted on hepatoxicity of ART on HIV 
patients(7,12,17), there is little knowledge on the comparison of the extent of liver 
damage in patients who are HIV/HBV co-infected in Malawi. The results of this study 
will contribute towards filling this gap and in turn the management HIV/HBV patients.
1.2.8.1 Research Question
Does HIV/HBV co-infection affect the changes in levels of ALT among HIV/HBV co­
infected compared to HIV mono infected among women on ART enrolled in the BAN 
study from 2004 to 2009 in Lilongwe Malawi (BAN study)?
1.2.9 Study Objectives
1.2.9.1 Objectives
1. Describe the social-demographic characteristics of HIV/HBV co-infected and 
HIV mono-infected women on ART enrolled in the BAN study from March 2004, 
to February 2009 in Lilongwe Malawi.
2. Compare the changes in the levels of ALT between HIV/HBV co-infected and 
HIV-mono infected women on ART enrolled in the BAN study from March 2004 
to February 2009 in Lilongwe Malawi.
3. Identify risk factors associated with changes in ALT levels among HIV/HBV co­
infected and HIV-mono infected women on ART enrolled in the BAN study from 
March 2004 to February 2009 in Lilongwe Malawi.
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CHAPTER TWO
2.0 METHODS
2.1 Introduction
This chapter describes the methods used in the study and procedures that were 
employed to ensure the validity of the results. It includes the design of the study, a 
description of the study population, data collection and study variables. The chapter 
ends with details of data management carried out, the statistical methods used, the 
diagnostic test used to measure validity of the findings, including tests for confounding 
and interaction.
2.2 Study Design and Description of the Secondary Study
This is secondary data analysis of the Breast Feeding, ART and Nutritional (BAN) 
study in Malawi. In this analysis the ALT profiles over time were compared among 31 
HIV/HBV co-infected and 513 HIV mono-infected women randomised into maternal 
ART arm of the BAN study. The subjects were followed over 20 follow ups for a period 
of 48weeks. ALT was used as continuous variable to track the mean change of the 
levels per follow-up, and was also used as categorical variable with categories normal; 
<2.5 times the upper limit of normal and abnormal; >2.5 times of the upper limit of 
normal.
2.3 Study Setting
The study participants were recruited from Bwaila antenatal clinic in Lilongwe Malawi. 
Samples were stored at University of North Carolina repository project Laboratory in 
Lilongwe, Malawi and there after shipped to Atlanta. Specimens were tested for 
Hepatitis virus at CDC Laboratory in Atlanta, Georgia, United states of America..
2.4 The Primary Study (BAN Study)
The BAN study was a 2 by 3 factorial randomised clinical trial conducted in Lilongwe 
Malawi. At delivery, women and their new-born were randomized to one of three, 28- 
week ART intervention arm with drugs given to the mother, infant, or neither—for 
prevention of HIV transmission during breastfeeding. The maternal ART regimen 
comprised Zidovudine, Lamivudine, and either NVP, Nelfinavir (NFV) or 
Lopinavir/ritonavir (LPV/r). Alanine-aminotransferase (ALT) was determined
antenatally, at delivery and 2, 4, 6, 8, 12, 18, 20, 24, 36 and 48 weeks postpartum. 
Details of the design are published elsewhere (21).
2.5 Study Population and Sampling
The proposed study utilized the data of 544 HIV positive women enrolled into BAN 
study from March 2004 to February 2009 at Bwaila antenatal clinic Lilongwe Malawi. 
This sample is based on 36% of women who were randomised into maternal ARV arm 
of the BAN study.
2.6 Data Sources
The data for this study were primarily from the BAN study conducted at Bwaila hospital 
Lilongwe Malawi. The socio-demographics information including age was collected 
using standard questionnaire. CD4 count were measured as part of 
full blood count, while ALT was measured as part of Liver function tests. Information 
on ART is included in the dataset. Hepatitis B diagnosis was done retrospectively at 
CDC Laboratory in Atlanta in 2008 when a sub study of prevalence of hepatitis B and 
transmission was conducted (22)
2.7 Data Management and Analysis
2.7.1 Measurements of Exposure and Outcome
2.7.1.1 Exposure variables
HBV infection (categorical) was measured in a sub study of prevalence of HBV 
conducted in 2008. The stored plasma was shipped from -800C storage in Lilongwe to 
repository at CDC Atlanta and tested at the CDCs division of viral Hepatitis. The 
plasma specimen from second and third trimester of pregnancy at pre-randomisation 
eligibility screening were tested for total antibody to hepatitis B core antigen(anti-HBc) 
and those anti-HBc-positive were assayed for Hepatitis surface antigen (HBsAg) and 
those HBsAg-positive were tested for hepatitis e antigen. Specimen found HBsAg 
positive underwent HBV DNA quantification (22). Based on HBsAg positivity the 
prevalence of HBV in this group of women was 5.6%.
2.7.1.2 Study outcome
ALT: plasma alanine aminotransferase (ALT) level was measured compared to the 
upper limit of normal. It was analysed as both a continuous and categorical variable.
ALT level of < 43IU/L is considered normal and >43 IU/L was abnormal or 
Transaminitis.
2.7.1.3 Potential Confounders
i. Socio-Demographic
> Age: Age in years at time of enrolment
ii. Biological
> Regimen of ART: The first line ART was ZDV, 3TC and NVP 
(Nevirapine based regimen), individuals who developed toxicity to 
ZDV were switched to Stavudine. On February 7, 2005, Nevirapine 
was discontinued as part of maternal HAART and was replaced with 
Nelfinavir. After February 7 2005 ZDV or DT4, 3TC and Nelfinavir 
(Nelfinavir based) was the first line ART. On January 25, 2006 
Nelfinavir was replaced by LPV/r and the first line regimen was ZDV 
or DT4, 3TC and LPV/r (LPV/r based). These changes were made 
for safety, availability and potency.
> CD4 count: number of cells/ ^l was categorised into Immune 
suppression groups according to CDC guidelines into
1. No immune suppression = CD4 count >=500 cells/ ^l
2. Moderate Immune suppressed= >=200 -500 cells/ul
3. Severe immune suppression = <200 cells/ ^l
> Hepatitis B surface antigen was measured using the Vitros 
Chemiluminescence Immunoassay (Ortho Clinical Diagnostics, 
Rochester, NY)
2.7.2 Data Management
The data from the original study was already in stata format. The data was cleaned 
and checked for duplicates and missing data. Renaming, replacement and recoding 
of relevant variables was done. All variables not needed for the current study were 
dropped. Continuous data that is required in categorical form were categorised. Data 
in wide format was converted into long format for analysis. Exploratory analysis to 
summarize the main characteristics of the data and to identify outliers, trends and data 
patterns was done using graphical methods like box plots and histograms. Normal
probability plots and histograms were used to determine if data has a normal 
distribution for all continuous variables.
2.7.3 Exploratory Analysis
Exploratory analysis was done to summarize the data and identify missing data trends, 
patterns and outliers. Histograms, skewness test and Shapiro wilk test were used to 
check if the continuous data is normally distributed. Non-parametric test was employed 
on all skewed data. Exploratory analysis of data was achieved using commands such 
as misstable, summarise in Stata, to view the patterns of missingness across the 
follow-ups.
2.7.4 Objective 1: Descriptive Analysis of Demographic Data
Descriptive analysis included generating a small dataset that included the first follow­
up and the last follow-up in stata. This was done to get a smaller dataset for descriptive 
analysis. All participants had first and last follow-ups regardless of the number of visits. 
All 544 participants were included in the descriptive analysis. Participants were 
categorised as HIV infected or HIV/HBV co-infected. The baseline characteristics for 
each group were summarised using median and interquartile ranges for all continuous 
skewed data, and simple proportions with confidence intervals were determined using 
exact methods for categorical variables. Continuous variables were compared using 
Wilcoxon rank sum test and Sign test between the two groups. Two way comparisons 
of frequencies of categorical data were done using Pearson’s chi squared-tests where 
the expected value is greater than or equal to 5 and Fischer’s exact where the 
expected cell value is less than 5. A p-value of <0.05 was considered as significant in 
all analysis.
2.7.5 Objective 2: Comparison of the Level of ALT at Baseline and Last Follow­
Up
A data set for 2 follow-ups was generated in stata, which included the first follow-up 
and the last follow-up to compare the change in ALT, from baseline to last follow-up. 
Wilcoxon rank sum was also used to compare ALT levels between the groups at 
baseline and at the last follow-up of each individual
2.7.6 Objective 3: Factors that Affect the Levels of ALT in the HIV/HBV co­
infected Individuals
All participants were included for the analysis even those who did not have all the 
follow ups. Generalised Linear Mixed Models was appropriate because it allows 
unbalanced or missing observations within-subject, unbalanced time intervals and 
allows various within-subject covariance structures. It also allows time to be treated as 
categorical or continuous. Univariate analysis GLMM was done to identify the 
variables to be adjusted for in the multivariate analysis. All variables with significant 
level below 0.05 were included in the GLMM model. GLMM analysis was used to 
estimate the effects of HBV on the levels of ALT over time. Models were adjusted for 
ART used (Nevirapine, Combivar, Nelfivar, stavudine LPV/r) and Visit number as 
determined in the univariate analysis. Wald statistic was used to select the more 
parsimonious model, the model with low Wald chi-square statistic was considered as 
the more parsimonious model. Backward elimination was used to build a parsimonious 
model.
All statistical tests were two sided and P -value <.05 was regarded as statistically 
significant. The results are reported as presented in the tables and graphs to meet the 
study’s objectives.
Limitations
The BAN study was designed to investigate the effect of ART in prevention of mother- 
to-child transmission of HIV-1 during Breastfeeding not specifically to answer this 
secondary research question. Pregnant women recruited into BAN study were not a 
true representative of the general women population and this may affect the 
extrapolation ability of the study findings. Information on alcohol consumption and use 
of other medication is not available, these can be potential confounders. Among other 
factors liver damage can be caused by alcohol consumption and use of medication 
i.e. contraceptives , aflatoxins in some, and anti-Tuberculosis drugs. If this information 
was available we could adjust in the analysis.
CHAPTER THREE
3.0 RESULTS
3.1 Introduction
The results are structured according to specific objectives of this study and also show 
the results of the analysis that was done to explore bias and control for confounding.
3.2 Study Population
The BAN study screened 3572 antiretroviral-naive, HIV-infected pregnant women 
attending 3 antenatal clinics in Lilongwe and enrolled 2367 women who met antenatal 
and postnatal eligibility criteria between March 2004 and February 2009. A total of 
2367 mothers and child pairs were included in the BAN study: 851 were randomised 
to maternal ART, 848 to infant NVP, and 668 to the enhanced control. The enhanced 
control arm had fewer women, because randomisation to the control arm was 
discontinued after March 2008 following the Data Safety and Monitoring Board 
(DSMB) recommendations. Of the 851 women randomised to the maternal art arm 
544 were made available for this analysis.
Figure 1: Consort Diagram
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3.3 Baseline Characteristics
A total of 544 women randomised into the maternal ART arm of the BAN study were 
analysed at baseline, of which 39 (7.23%) women were initiated on Nevirapine based 
regimen as their first line regimen, due to change in the FDA guidelines the first line 
ART regimen changed to Nelfinavar based regimen and 107 (20.11 %) of the women 
were initiated on Nelfinavar based regimen as their first line regimen. Two years later 
FDA guidelines changed and Nelfinavir was replaced with Lopinavir/Ritonavir as first 
line regimen and 389 (72.56) women were initiated on LPV/r based regimen. Median 
age at enrolment was 26 (IQR:22-29).,
3.4 Clinical Laboratory Characteristics
Of 544 women analysed at baseline 31 (5.6%) were HIV/HBV co-infected. At baseline 
median ALT was 13(10.5-16), and median CD4 count was 435.5 cells/gl (331-565.5), 
2 (0.37%) of the women had severe immune suppression (CD4 less than 200 (cells/gl) 
and majority (62.87%) of the women were moderately immune suppressed and 
36.76% had CD4 cell count above 500 cells/ul.
Table 1: Baseline characteristics and ART regimens stratified by HIV/HBV co-infection
Characteristics Overall (Median/ 
Percentage)
HIV/HBV(31) HIV(513) p-value
Age (Median) 26 (22-29) 24(22-29) 26(22-29) 0.29¥
ALT (Median) 13 (10.5-16) 14(11-18) 13(10-16) 0.09f
ART regimen (%)
AZT/DT4/3TC/ LPV/r 386 (72.56) 18 (60.00) 371 (73.31)
AZT/DT4/3TC/ Nelfinavar 107 (20.11) 11 (36.67) 96 (19.12) 0.70f
AZT/DT4/3TC/Nevirapine 39 (7.23) 1 (3.33) 38 (7.57)
Absolute CD4 (cells/^l) 435.5 (331-565.5) 442 (367-558) 435(327-566) 0.42
Absolute CD4 Count
>500 cells/ l^ ) 200 (36.76) 13 (41.94) 187 (58.06) 0.62
>200 - <500 cells/ l^ 342 (62.87) 18 (58.06) 324 (63.16)
<200 cells/ l^ 2 (0.37) 0 2 (0.39)
Fischer's exact p-f value for binary variables.
¥ Wilcoxon rank sum test for skewed variables 
* Variable significant at the 5% level of significance
3.4.1 Baseline Characteristics Stratified by HIV/HBV co-infection
Most baseline characteristics were similar between the HIV/HBV co-infected and HIV 
mono-infected women (Table1). However those co-infected were likely to have slightly 
elevated ALT compared to HIV mono-infected (p-value=0.10).The median levels of 
ALT were significantly higher 14 IU/L (11-18) vs. 13 IU/L (10-16)in HIV/HBV co­
infected patients (p, 0.09).Comparing ALT levels at baseline and the last follow-up the 
results showed a significant difference (p, <0.001).Median ALT level was 14 IU/L (10­
16) compared to 19 IU/L (16-26) of the last follow-up
3.5 Change of ALT over Time among HIV/HBV Co-Infected and HIV Mono­
infected Women
To check the changes of ALT levels over time, margins of the final model with an 
interaction term visit and HIV/HBV co-infection were calculated and the predicted 
changes of ALT levels were plotted. Figure (2) shows predicted levels of ALT at each 
visit. Predicted levels of ALT consistently higher among HIV/HBV co-infected women 
through the visits. Figure (3) shows the changes in the levels of ALT over the follow 
up period. HIV/HBV co-infected women had on average higher median ALT levels. At 
baseline the levels were almost similar, but after four weeks into the study co-infected 
women started experiencing ALT elevation, and it picked at 8 weeks and then started 
going down to normal levels at 36 weeks.
3.6 Factors associated with changes in the levels of ALT
Table (2 & 3) shows predictors of ALT abnormality. Being HIV/HBV co-infected was 
associated with increased levels of ALT by 6.30 IU/L (1.87-7.47 p= 0.002). Women 
that were initiated on Nelfinavar based regimen had on average increased levels of 
the ALT throughout the study period ALT by 2.74 IU/L (0.37-5.12 p=0.02) Although 
not significant individuals on Nevirapine based regimen had increased levels of ALT 
compared to their counterparts who were initiated on LPV/r based regimen. In addition 
women who were severely immune suppressed had increased ALT 11.95 (P=0.03). 
The results also shows an increase in average levels of ALT at each subsequent visit. 
Each additional visit was associated with an increase in ALT level of 0.63 (P=0.0001).
Figure 2: Margin plot for Predicted ALT levels per visit for both groups
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Figure 3: Profile plot changes of levels of ALT stratified by HIV/HBV co-infection
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Table 2: Factors Associated with the changes in the levels of ALT
Variable Un-adjusted P_value Adjusted P_value
Coefficient Coefficient
HIV+/HBV - Ref
HIV+/HBV+ 6.37 (1.87-7.47) 0.01 6.78 (1.84-10.48) 0.05
Age -0.0001(-0.00001-
1.27)
0.10
ART regimen
AZT/DT4/3TC/ Kaletra Ref
AZT/DT4/3TC/ Nelfinavar 2.74 (0.37-5.12) 0.02 -0.53 (-4.37-3.31)
0.79
AZT/DT4/3TC/Nevirapine 3.78 (-0.778.340 0.10 0.90 (-6.32-8.13)
0.81
Absolute CD4 Count
>500 cells/ pl ) Ref Ref
>200 - <500 cells/ pl -2.67 (-5.70. 0.09 -0.81 (-3.99-2.38) 0.62
<200 cells/ pl 11.95 (0.92-22.99) 0.03 11.32 (0.29-22.34 0.04
Visit-number 0.63 <0.01 0.63 ( 1.06-1.12) <0.001
Table 3: Predictors of Elevated ALT
Variable Un-Adjusted OR P-value Adjusted-OR P-value
(95% CI) (95% CI)
HIV+/HBV- Ref
HIV+/HBV+ 3.28 (1.43-9.03) 0.01 3.27 (1.48-7.09) 0.01
Age 1.02 (0.96-1.07) 0.43
ART regimen
AZT/DT4/3TC/ Kaletra Ref
AZT/DT4/3TC/ Nelfinavar 3.22 (1.85-5.59) <0.001 0.85 (0.5-1.04) 0.54
AZT/DT4/3TC/Nevirapine 2.69 (1.04-7.01) 0.04 1.9 (0.13-4.8) 0.13
Absolute CD4 Count
>500 cells/ l^ ) Ref Ref
>200 - <500 cells/ l^ 0.38 (0.15-1.00) 0.05 1.24 (0.83-1.87) 0.28
<200 cells/ l^ 3.51 (0.75-16.27) 0.12 1.03 (0.70-6.49) 0.18
Visit-number
1.19 (1.11-1.27)
<0.001 1.12 (1.15-1.27) <0.001
3.7 Factors associated with Elevated ALT
Transaminitis is defined as elevated ALT levels above 43 IU/L. to check for the risk 
factors of Elevated ALT between HIV/HBV co-infected and HIV mono-infected 
individuals ALT was categorised into high (>43 IU/L) and normal (<.43 IU/L). Table (3) 
shows results of multiple regression analysis with categorical ALT as dependent 
variable. HIV/HBV co-infected women were 3.28 (1.43-9.03 p= 0.01) times more likely 
to have higher ALT (Transaminitis), compared to their HIV mono-infected 
counterparts. Individuals that were initiated on Nelfinavar as first line ART were 3.22 
(1.85-5.59 p=0.001) more likely to have transaminitis compared to those that were 
initiated on LPV/r based regimen. Moderately immune suppressed women (CD4 count 
of between 200 to 500 cells/dl) were 0.38 times less likely to have transaminitis (0.15­
1.00) while women who were severely immune suppressed were 3.51 times more 
likely to have transaminitis. Overall there was an increase in the level of ALT per each 
subsequent visit. For each subsequent visit, there was increase in average ALT 
(0.506; p-value 0.0001).
CHAPTER FOUR
4.0 DISCUSSION
4.1 Introduction
This chapter discusses the findings for the study outcome. We will discuss the factors 
that are associated with our outcome, starting with the main exposure of the study 
which is HIV/HBV co-infection. Relationships between the findings in our study 
compared to findings from other studies are explored and possible reasons for our 
findings are also discussed. The chapter also gives an overview of the relevance of 
the findings with regards to HIV, HBV and Liver disease and also highlights the 
limitations of the study.
4.1.1 Effect of HIV/HBV co-infection among women on ART
This study assessed changes of the levels of ALT to determine the effect of HIV/HBV
co-infection on liver disease using ALT as proxy, among women on ART enrolled in 
the Breast feeding Antiretroviral and Nutrition (BAN) study in Malawi.
Our results show that HIV/HBV co-infection had an impact on the levels of ALT. At 
baseline there were no clear difference in the levels of ALT among HIV/HBV co­
infected individuals and HIV infected. Higher Median serum ALT enzyme levels, were 
reported among HIV/HBV co-infected women from 4 weeks after ART initiation picked 
at week 8 up to 5 times upper limit of normal and started going down to normal levels 
(Figure 2). In addition Individuals that were initiated on Nevirapine and Nelfinavar 
based regimens had increased chances of developing transaminitis compared to 
those that were initiated on LPV/r based regimen. Immune suppression at baseline 
was also significantly associated with higher levels of ALT. The findings of this study 
are consistent with previous study conducted among ART naive population in Nigeria 
B.Goni et al. (23). The study showed that HIV/HBV co-infected patients had an 
Increased median ALT levels i.e., 42.12 IU/l vs. 27.86 IU/l, (P = 0.038). Aluwami H O, 
reported high levels of ALT among HIV/HBV co-infected individuals(23).
Increased risk of liver disease in HIV/HBV co-infected women on ART can be 
explained by Immune reconstitution after ART initiation, which is the immune mediated 
destruction of the liver cells that are infected by the HBV virus after ART initiation. The
individual course of HBV infection depends on the interaction between host immune 
system and the virus replication. The normal HBV progression in individuals who are 
not HIV infected can be divided into four phases, immune tolerance, immune 
clearance, low or Non_replicative and reactivation. Immune tolerance phase patients 
have High levels of HBV DNA, with mildly elevated ALT and minimal histological 
activity. After a period of immune tolerant phase depending on the age individuals may 
enter into immune active phase where patients experience fluctuating HBV DNA levels 
and increased ALT and liver histologic activity which indicates immune mediated 
histologic damage.90 % of individuals proceed to inactive where HBV DNA is 
decrease to below detectable levels. This phase can last for life if the patient’s 
immunity is not compromised. In immune compromised individuals i.e. HIV infected 
individuals can experience HBV infection reactivated caused by immune reconstitution 
by ART.
4.1.2 Change of ALT Levels per Visit
On average each subsequent visit was associated with an increase in the level of ALT 
the increase was much higher in individuals Co-infected with HIV/HBV.Price J te.al 
recorded accelerated progression of liver disease in the presence of HIV, and was 
attributed to lower rates of spontaneous clearance of HBeAg, increased HBV 
replication, and higher rate of loss of anti-HB and reactivation of HBV (24). They 
indicated that co-infected individuals also experienced an increased progression to 
cirrhosis and higher liver related mortality. In addition, HIV/HBV co-infected individuals 
experienced frequent hepatic flares of ALT over the 48 weeks of follow-ups. These 
flares can be attributed to immune reconstitution due to a rapid increase in cytotoxic T 
cells, leading to immune-mediated destruction of HBV-infected hepatocytes (16). 
These findings are in line with a study by Hans H et al (25), which reported 26(3.4%) 
patients experienced severe hepatoxicity out of the 755 patients who were receiving 
ART.
4.1.3 The effects of ART on the Levels of ALT
Liver toxicity is one of the most common adverse events associated with ART. The 
clinical presentation can range from mild asymptomatic increases in serum 
transaminases to liver failure(26). In retrospective studies, the incidence of ART-
related severe hepatotoxicity has been estimated to be 10%, and life-threatening 
events occur at a rate of 2.6 per 100 person years(24). While all antiretroviral drugs 
have some risk of hepatotoxicity, some are more implicated than others.
4.1.4 Nevirapine based Regimen
In agreement with other studies this study showed that Nevirapine is associated with 
increased ALT levels. Individuals on Nevirapine had increased levels of ALT compared 
to their to individuals who were Kaletra based regimen. The potential of increased liver 
toxicity of a Nevirapine based regime compared to other regimens has been 
previously described by Paul, E (27)(28). Paul reported toxicity in 1 (5%) of 21 
subjects on Nelfinavir based regimen and 5 (29%) of 17 subjects randomized to 
Nevirapine. Among the individuals randomised to the Nevirapine group, 1 subject 
developed hepatic failure and died, and another developed Stevens-Johnson 
syndrome. Esteban,E, (29) reported 12 percent incidence of Hepatoxicity among ART 
naive patients receiving Nevirapine based regimen. In addition Nevirapine has been 
implicated to cause hypersensitivity which includes skin rash, eosinophilia and 
Hepatitis (23).The findings of this study are consistent with literature. Antonio R et el. 
also reported increased levels of ALT among patients on Nevirapine (30).
4.1.5 LPV/r based Regimen
LPV/r was associated with decreased ALT level of -2.76 IU/L (p. 0.013) in the current 
study. In contrast Sulkowski et al reported Lopinavir/Rotinativir to be toxic to the liver. 
Sulkowski, et al. recorded severe hepatotoxicity defined as elevated transaminases 
more than 5 times normal in 27.3% of patients on LPV/R treatment. These conflicting 
findings can be attributed to change of first line regimen in BAN study. In June 2005 
BAN study changed the first line drugs from Nevirapine to Lopinavir/Rotinativir due to 
FDA recommendations (25). Not all individuals were initiated on LPV/r at baseline. 
Individuals who were enrolled before June 2005 were initiated on Nevirapine as a first 
line drug.
4.1.6 Nelfinavir based regimen
Nelfinavir has been recorded to cause low rates of liver toxicity, Mira, J(31) reported 
low incidence of severe hepatoxicity among patients on Nelfinavir based regimen
compared to Nevirapine. A 4268 patient’s prospective and retrospective clinical trial 
and a prospective cohort study reported Nelfinavir to be associated with the lower 
rates of severe hepatotoxicity. The low rate of severe hepatotoxicity for Nelfinavir was 
reported even among participants that were co-infected with hepatitis viruses(32). 
This study shows Nelfinavir based regimen to be associated with increased levels of 
ALT, these findings are not consistent with other studies. These contrasting findings 
can be explained by the change in first line regimen the BAN study. First line ART 
regimen was switched from Nevirapine based regime to Nelfinavar based and then to 
LPV/r in a space of one year due to safety, availability and potency. So the high levels 
may not explicitly be attributed to Nelfinavir.
4.1.7 CD4 cell count and levels of ALT
Low CD4 cell count (<200 cells/ul) was associated with high levels of ALT in the 
current study. The effect of low CD4 count on liver disease has been extensively 
studied and there are conflicting findings on the effect of low CD4 cell count on the 
liver damage. H.O Olawumi et el reported increased rates of hepatotoxicity among 
patients with CD4 cell count of less than 200 cells/ul (23) among ART naive population 
in Nigeria. P. J peters reported no association between Low CD4 cell count and 
hepatotoxicity among women on Nevirapine-based ART(33). These contradicting 
findings may be explained by understanding the association between Low CD4 cell 
count and Liver disease. Cassidy et el reported low CD4 cell count in patients with 
liver cirrhosis but HIV negative. He further reported sequestration of peripheral blood 
cells by the spleen in patients with liver disease , which can lead to low absolute CD4 
cell count, but with normal CD4 percentages(26).
4.2 Limitations
The BAN study was designed to investigate the effect of ART in prevention of mother- 
to-child transmission of HIV-1 during Breastfeeding not specifically to answer this 
secondary research question. Pregnant women recruited into BAN study were not a 
true representative of the general women population this may affect the extrapolation 
ability of this study findings. Information on alcohol consumption and use of other 
medication is not available, these can be potential confounders. Among other factors 
liver damage can be caused by alcohol consumption and use of other medication i.e.
contraceptives, and anti-Tuberculosis drugs. If this information was available we could 
adjust in the analysis.
4.3 Conclusion
In conclusion our study shows that individuals co-infected with HIV/HBV are at a high 
risk of liver disease. Our study further strengthen the need for screening of all HIV 
positive patients for HBV before initiating treatment and also caution to be taken when 
choosing the first line ART for individuals co-infected with HIV/HBV since they are at 
very high risk of liver damage.
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NHSRC using standard forms obtainable from the NHSRC Secretariat.
• QUESTIONS: Please contact the NHSRC on telephone number +265 I 789 400 314 or by email 
on doccentreYijmalawi.net.
• OTHER: Please be reminded to send in copies of your final research results for our records 
(Health Research Database).
Kind regards from the NHSRC Secretariat.
—
For CHAIRPERSOljh NATIONAL HEALTH SCIENCES RESEARCH COMMITTEE
T Promoting Ethical Conduct of Research
Executive Committee: D rC M lwansam ho (Chairperson). Prof. E. Molyneux (Vice-Chairperson) 
Registered with the USA Office for Human Research Protections (OHRP) as an International IRB
IRB Number IRB00003905 FWA00005976
6.3 Appendix 3: HREC-90-06-Chasela Approval Letter 
11th June 2007
Mr Charles Chasela
c/o Professor Patrick Wall
UCD School of Public Health & Population Science 
Woodview House 
Belfield 
Dublin 4
RE: HREC-90-06-Chasela -  Epidemiology of Hepatitis B and C virus and human 
immunodeficiency virus
Dear Mr Chasela
Thank you for your response to the Human Research Ethics Committee 
(24/06/07). The decision of the Committee is as follows:
As you have met the Committee's requirement, namely that you have 
obtained local ethical approval, the Committee has approved this study. 
However, we require a copy of the protocol that was approved and 
approval is based on your strict adherence to the protocol as approved by 
the Ministry of Health in Malawi. Any amendments, additions or revisions 
must be approved locally (Ministry of Health, Malawi) and notified to the 
UCD Human Research Ethics Committee.
Approval is time limited -  any extensions to the original timeframe for the
approved study will need to be approved by the Committee. Any changes 
to the original proposal will need to be approved by the Committee. The 
Committee should be notified of any adverse events that occur during 
the conduct of your research.
If you have any queries please contact the Research Ethics Office.
Yours sincerely,
Dr Michelle Butler
Chairman, Human Research Ethics Committee
